These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29506478)

  • 1. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    Lee DW; Lee KH; Kim HJ; Kim TY; Kim JS; Han SW; Oh DY; Kim JH; Im SA; Kim TY
    BMC Cancer; 2018 Mar; 18(1):252. PubMed ID: 29506478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
    Lv Y; Liang R; Hu X; Liu Z; Liao X; Lin Y; Yuan C; Liao S; Li Q; Zhang J; Li Y
    Pharmazie; 2014 Oct; 69(10):759-63. PubMed ID: 25985566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
    Bando H; Yamada Y; Tanabe S; Nishikawa K; Gotoh M; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Gastric Cancer; 2016 Jul; 19(3):919-26. PubMed ID: 26474989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
    Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
    World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Qin S; Bai Y; Lim HY; Thongprasert S; Chao Y; Fan J; Yang TS; Bhudhisawasdi V; Kang WK; Zhou Y; Lee JH; Sun Y
    J Clin Oncol; 2013 Oct; 31(28):3501-8. PubMed ID: 23980077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
    Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
    Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
    Koizumi W; Takiuchi H; Yamada Y; Boku N; Fuse N; Muro K; Komatsu Y; Tsuburaya A
    Ann Oncol; 2010 May; 21(5):1001-5. PubMed ID: 19875759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
    JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
    Wang ZQ; Zhang DS; Xu N; Luo DY; Deng YH; Wang FH; Luo HY; Qiu MZ; Li YH; Xu RH
    Chin J Cancer; 2016 Jan; 35():8. PubMed ID: 26739998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Lee J; Shin SJ; Chung IJ; Kim TW; Chun HG; Shin DB; Kim YH; Song HS; Han SW; Kim JG; Kim SY; Choi YJ; Chung HC
    Invest New Drugs; 2014 Jun; 32(3):561-8. PubMed ID: 24573743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
    Ohkawa S; Okusaka T; Isayama H; Fukutomi A; Yamaguchi K; Ikeda M; Funakoshi A; Nagase M; Hamamoto Y; Nakamori S; Tsuchiya Y; Baba H; Ishii H; Omuro Y; Sho M; Matsumoto S; Yamada N; Yanagimoto H; Unno M; Ichikawa Y; Takahashi S; Watanabe G; Wakabayashi G; Egawa N; Tsuda M; Hosotani R; Hamada C; Hyodo I
    Br J Cancer; 2015 Apr; 112(9):1428-34. PubMed ID: 25880004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.